Phase 1 KSD-101 Trial for EBV-Associated Hematological Malignancies
Summary
NIH ClinicalTrials.gov registered a Phase 1 study (NCT07532746) evaluating KSD-101 for relapsed or refractory EBV-associated hematological malignancies. The single-arm trial will assess safety, tolerability, preliminary efficacy, immune response, and quality of life in participants treated with KSD-101.
What changed
NIH ClinicalTrials.gov added a new Phase 1 clinical trial registration (NCT07532746) for KSD-101, an investigational treatment for relapsed or refractory EBV-associated hematological malignancies. The study will enroll participants to evaluate safety, tolerability, preliminary efficacy, immune response, and quality of life outcomes.
For clinical investigators, pharmaceutical sponsors, and healthcare providers involved in EBV-related hematology research, this registration signals active enrollment activity and provides standardized study information including eligibility criteria, interventions, and outcome measures.
What to do next
- Monitor ClinicalTrials.gov for study updates
Archived snapshot
Apr 16, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological Malignancies
Phase 1 NCT07532746 Kind: PHASE1 Apr 16, 2026
Abstract
The main purpse of this study is to evaluate the safety and tolerability of KSD-101 in the treatment of relapsed or refractory EBV-associated hematological malignancies,to preliminarily explore the clinical efficacy ,evaluate the immune response to KSD-101 for the treatment in Patients with EBV-associated hematological diseases and the improvement in subjects' quality of life (QOL) after KSD-101 treatment.
Conditions: Relapsed or Refractory EBV-associated Hematological Malignancies
Interventions: KSD-101
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.